<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394548</url>
  </required_header>
  <id_info>
    <org_study_id>15-023</org_study_id>
    <nct_id>NCT02394548</nct_id>
  </id_info>
  <brief_title>Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer</brief_title>
  <official_title>A Phase I Trial Of Intensity-Modulated Radiation Therapy (IMRT) Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Non-Small Cell Lung Cancer (NSCLC) And Limited-Stage Small Cell Lung Cancer (LS-SCLC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is examining the benefit of a novel radiation planning approach on the
      likelihood of developing severe esophagitis (irritation and inflammation of the esophagus)
      during the course of radiation therapy with concurrent chemotherapy which is associated with
      very painful and difficult swallowing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase I clinical trial, which tests the safety of an investigational
      intervention and also tries to define the appropriate dose of the investigational
      intervention to use for further studies. &quot;Investigational&quot; means that the intervention is
      being studied.

      The U.S. Food and Drug Administration (FDA) has approved radiation with chemotherapy as a
      treatment option for your disease.

      Currently, there are no established rules to avoid esophagitis in the treatment of lung
      cancer with radiation therapy. We have developed an IMRT-based technique, termed CEST, to
      reduce the radiation dose to the part of the esophagus that is located opposite to the tumor.
      The reason behind this approach is that a lower radiation dose causes less esophagus
      inflammation and irritation and, therefore, may preserve the swallowing function of the
      esophagus better. In our clinical experience, reducing the radiation dose to part of the
      esophagus in this fashion has shown the potential to dramatically decrease the likelihood of
      severe esophagitis in many though not all people with lung cancer. We therefore wish to
      analyze this technique further.

      There is no firm data to indicate that different chemotherapy regimens given at the same time
      of radiation therapy result in different rates of esophagitis. The Investigators will,
      therefore, allow any type of standard-of-care chemotherapy regimen at the discretion of the
      patient's medical oncologist.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE)</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Esophagitis will be measured using the Common Toxicity Criteria for Adverse Effects (CTCAE) v4 scoring scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Acute Esophagitis (RTOG)</measure>
    <time_frame>Baseline , up to 3 Months</time_frame>
    <description>Esophagitis will be measured using the historical Radiation Therapy Oncology Group (RTOG) scoring scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline, up to 2 Years</time_frame>
    <description>Adverse events will be measured using CTCAE v4 scoring scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Local and Regional Failure</measure>
    <time_frame>2 Years</time_frame>
    <description>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>2 Years</time_frame>
    <description>Follow-up time will be calculated from the date of registration to the date of death or the last follow-up date on which the patient was reported alive. Overall survival rates will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival Time</measure>
    <time_frame>2 Years</time_frame>
    <description>Follow-up time will be calculated from the date of registration to the date of death or the last follow-up date on which the patient was reported alive. Median survival time will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Contralateral Esophagus Sparing Technique (CEST)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Contralateral Esophageal Sparing Technique (CEST)</intervention_name>
    <description>Determine whether CEST decreases rate of severe acute esophagitis</description>
    <arm_group_label>Contralateral Esophagus Sparing Technique (CEST)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet the following criteria on screening examination to be eligible to
        participate in the study.

          -  Histologically or cytologically proven diagnosis of NSCLC or SCLC

          -  NSCLC, patients with clinical stage IIB-IV patients (AJCC, 7th ed.) are eligible, and
             for SCLC, limited-stage patients are eligible, if documented to be a candidate for
             definitive radiation and concurrent chemotherapy in the radiation oncologist or
             medical oncologist clinic note.

               -  Stage IV NSCLC patients are eligible only if they have a solitary brain
                  metastasis

               -  Patients with non-malignant pleural effusion are eligible. --- If a pleural
                  effusion is present, the following criteria must be met to exclude malignant
                  involvement:

                    -  When pleural fluid is visible on both the CT scan and on a chest x-ray, a
                       pleuracentesis is required to confirm that the pleural fluid is
                       cytologically negative.

                    -  Exudative pleural effusions are excluded, regardless of cytology;

                    -  Effusions that are minimal (ie, not visible on chest x-ray) that are too
                       small to safely tap are eligible.

          -  Gross tumor (primary tumor or involved lymph node) must be within 1 cm of esophagus on
             the most recent chest CT scan.

          -  ECOG performance status 0-1 within 30 days prior to registration;

          -  Age â‰¥18

          -  Women of childbearing potential must indicate that there is not a possibility of being
             pregnant at the time of enrollment or have a negative serum pregnancy test prior to
             the initiation of radiation therapy.

          -  Women of childbearing potential and male participants must practice adequate
             contraception.

          -  Patient must provide study-specific informed consent prior to study entry.

        Exclusion Criteria:

        Participants who exhibit any of the following conditions at screening will not be eligible
        for admission into the study.

          -  Greater than minimal, exudative, or cytologically positive pleural effusions

          -  Tumor suspected or known to invade the esophagus

          -  Prior chemotherapy if this precludes administration of concurrent chemotherapy for
             protocol treatment. Note that induction chemotherapy is allowed as long as concurrent
             chemotherapy is possible.

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note,
             however, that HIV testing is not required for entry into this protocol. The need to
             exclude patients with AIDS from this protocol is necessary because the treatments
             involved in this protocol may be significantly immunosuppressive. Protocol-specific
             requirements may also exclude immuno-compromised patients.

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception; this exclusion is
             necessary because the treatment involved in this study may be significantly
             teratogenic.

          -  Any history of allergic reaction to chemotherapies used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Willers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>February 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2020</results_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Henning Willers, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Locally advanced, inoperable non-small cell lung carcinoma</keyword>
  <keyword>Limited stage small cell lung carcinoma</keyword>
  <keyword>Acute esophagitis</keyword>
  <keyword>Intensity-modulated radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02394548/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant was consented but never began treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Contralateral Esophagus Sparing Technique (CEST)</title>
          <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
Contralateral Esophageal Sparing Technique (CEST): Determine whether CEST decreases rate of severe acute esophagitis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Contralateral Esophagus Sparing Technique (CEST)</title>
          <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
Contralateral Esophageal Sparing Technique (CEST): Determine whether CEST decreases rate of severe acute esophagitis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="51" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE)</title>
        <description>Esophagitis will be measured using the Common Toxicity Criteria for Adverse Effects (CTCAE) v4 scoring scale</description>
        <time_frame>up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contralateral Esophagus Sparing Technique (CEST)</title>
            <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
Contralateral Esophageal Sparing Technique (CEST): Determine whether CEST decreases rate of severe acute esophagitis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE)</title>
          <description>Esophagitis will be measured using the Common Toxicity Criteria for Adverse Effects (CTCAE) v4 scoring scale</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Higher Acute Esophagitis (RTOG)</title>
        <description>Esophagitis will be measured using the historical Radiation Therapy Oncology Group (RTOG) scoring scale</description>
        <time_frame>Baseline , up to 3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contralateral Esophagus Sparing Technique (CEST)</title>
            <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
Contralateral Esophageal Sparing Technique (CEST): Determine whether CEST decreases rate of severe acute esophagitis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Acute Esophagitis (RTOG)</title>
          <description>Esophagitis will be measured using the historical Radiation Therapy Oncology Group (RTOG) scoring scale</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse events will be measured using CTCAE v4 scoring scale</description>
        <time_frame>Baseline, up to 2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contralateral Esophagus Sparing Technique (CEST)</title>
            <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
Contralateral Esophageal Sparing Technique (CEST): Determine whether CEST decreases rate of severe acute esophagitis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse events will be measured using CTCAE v4 scoring scale</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Local and Regional Failure</title>
        <description>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline</description>
        <time_frame>2 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate</title>
        <description>Follow-up time will be calculated from the date of registration to the date of death or the last follow-up date on which the patient was reported alive. Overall survival rates will be estimated using the Kaplan-Meier method.</description>
        <time_frame>2 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival Time</title>
        <description>Follow-up time will be calculated from the date of registration to the date of death or the last follow-up date on which the patient was reported alive. Median survival time will be estimated using the Kaplan-Meier method.</description>
        <time_frame>2 Years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment up to 2 years</time_frame>
      <desc>Serious adverse events were defined as adverse events with a grade of 3 or higher that were deemed to be possibly, probably, or definitely related to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Contralateral Esophagus Sparing Technique (CEST)</title>
          <description>IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
Contralateral Esophageal Sparing Technique (CEST): Determine whether CEST decreases rate of severe acute esophagitis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>white blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gerd</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oral Thrush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dermatitis Radiation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Henning Willers</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-5184</phone>
      <email>hwillers@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

